Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7Thoracic 6Dermatologic 5Head & Neck 4Gastrointestinal 3Breast 3Other solid neoplasm 1Gynecologic 1

Conditions

Solid Tumors 2Solid Tumor, Adult 2Advanced Solid Tumors 2Advanced Solid Tumor 2Advanced Refractory Solid Tumors 2Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Mesothelioma, Malignant 1Melanoma 1MSI-H Advanced Colorectal Cancer 1Immune-related Adverse Event 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Malignant Solid Tumors 1Advanced Malignant Solid Tumor 1

Interventions

pembrolizumab 10Nivolumab 5Granulocyte Colony-Stimulating Factor 4atezolizumab 3Ipilimumab 3Ifosfamide 3Etoposide 3tislelizumab 2sargramostim 2durvalumab 2Thiotepa 2Paclitaxel 2Mesna 2Melphalan 2Filgrastim 2Docetaxel 2Cyclophosphamide 2Carboplatin 2Busulfan 2tazemetostat 1spartalizumab 1regorafenib 1pegylated granulocyte colony-stimulating factor 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1etoposide phosphate 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Immune Checkpoint Inhibitors × Other solid neoplasm × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡